Nucleosides with 2'-O-modifications

Details Nucleosides with 2'-O-modifications Nucleosides with 2'-O-modifications

1995-04-20

1998-05-12

Kunz, Gary L.

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

536 261, 536 245, 536 243, C07H 1910, C07H 1920, C07H 2102

Patent

active

057506736

ABSTRACT:
Compounds of the formula ##STR1## wherein R.sub.1 and R.sub.2 are each independently of the other hydrogen or a protecting group, or
R.sub.1 has those meanings and
R.sub.2 is a radical forming a phosphorus-containing nucleotide bridge group;
B is a purine or pyrimidine radical or an analogue thereof; and
R.sub.3 is OH, F or (CF.sub.2).sub.n CF.sub.3 wherein n is a number from 0 to 7, and oligonucleotides that comprise those nucleosides are described.

REFERENCES:
patent: 5506351 (1996-04-01), McGee
Iribarren et al. Proc. Natl. Acad. Sci. 87:7747-7751, 1990.
R. Walker et al., Nucleoside Analogues Chemistry, Biology and Medical Applications, Table of Contents (1979).
J. A. Martin et al., American Chemical Society, Design of Inhibitors of Herpes Simplex Virus Thymidine Kinase, Chapter 7, (1989).
V. E. Marquez, American Chemical Society, Design, Synthesis and Antiviral Activity of Nucleoside and Nucleotide Analogues, Chapter 10 (1989).
W. Muller, Institut furPhysiologische Chemie, Abteilung "Angewandte Molekularbiologie", Universitat, Duesbergweg, 6500 Mainz, W. Germany, pp. 274-279 (1979).
J. C. Martin, Nucleotide Analogues as Antiviral Agents, ACS Symposium Series 401, Table of Contents (1988).
W. Prusoff et al., Yale Univ. Sch. of Med. Dept. of Pharm. pp. 281-318 (1979).
T. Merigan et al., Stanford Univ. Div. of Infectious Diseases, pp. 395-407 (1979).
A. Rossi, Institute Nazionale Tumori, pp. 409-436 (1979).
R.W. Sidwell, Research Professor of Biology and of Animal, Dairy and Veterinary Sciences, Utah State Univ., pp. 337-362 (1979).
F. M. Schabel, Jr., Southern Research Institute, Birmingham, Ala., pp. 363-394 (1979).
S. T. Crooke et al., Antisense Research and Applications Eds., CRC Press, Boca Raton, pp. 273-288, (1993).
G. Bott et al., J. Am. Chem. Soc., vol. 102, pp. 5618-5626 (1980).
Froehler, BC et al. Tetrahedron Letters 34(1993), pp. 1003-1006.
Lesnik, E.A. et al., Biochemistry 32(1993), pp. 7832-7838.
Chemical Abstracts 122(1995), abstract No. 56416v.
Beaucage, S.L., Iyer, R., Tetrahedron 48:2223-2311 (1992).
Mattiucci, M.D., Bischofberger, N., Annual Reports in Medicinal Chemistry, 26:287-296 (1991).
Helene, C., Toulme., J.J. Biochimica et Biophysica Acta 1049:99-125 (1990).
Marquez, V.E., Lim, M.I., Medicinal Research Reviews 6:1-40 (1986).
Uhlmann, E., Peyman A., Chemical Reviews, 90:543-584 (1990).
Sonveaux E., Bioorganic Chemistry 14:274-325 (1986).
Marky, L.A., Breslauer, K.J., Biopolymers 26:1601-1620 (1987).
Cook, P.D., Anti-Cancer Drug Design 6:585-607 (1991).
Uwe English et al., Angewandte Chemie Int. Ed. 30; pp. 613-722, (1991).

Affiliated with

Also associated with

Rating

Nucleosides with 2'-O-modifications does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nucleosides with 2'-O-modifications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nucleosides with 2'-O-modifications will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-980138